Cargando…
Quality problems of clinical trials in China: evidence from quality related studies
BACKGROUND: Recently, the quality of clinical trials conducted in China has made considerable progress. However, clinical trials conducted in China still fall below the global average standard. The aim of this systematic review was to assess studies that investigated the quality of clinical trials c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034627/ https://www.ncbi.nlm.nih.gov/pubmed/35461304 http://dx.doi.org/10.1186/s13063-022-06281-1 |
_version_ | 1784693149680009216 |
---|---|
author | Fan, Jin Liu, Xiaobo Li, Yuxi Xia, Haisha Yang, Rong Li, Juan Zhang, Yonggang |
author_facet | Fan, Jin Liu, Xiaobo Li, Yuxi Xia, Haisha Yang, Rong Li, Juan Zhang, Yonggang |
author_sort | Fan, Jin |
collection | PubMed |
description | BACKGROUND: Recently, the quality of clinical trials conducted in China has made considerable progress. However, clinical trials conducted in China still fall below the global average standard. The aim of this systematic review was to assess studies that investigated the quality of clinical trials conducted in China, summarize the issues, and provide suggestions for conducting high-quality clinical trials in China. METHODS: We comprehensively searched studies that investigated the quality of clinical trials conducted in China in the following databases from inception to December 1, 2021: National Knowledge Infrastructure, the Chinese Science and Technology Periodical Database, WanFang Data, China Biology Medicine, PubMed, and Embase. We then analyzed the issues in clinical trial registration, ethics review, implementation, and reporting. SPSS 25.0 software was used for data analysis. The data synthesis was conducted using summary statistics and a narrative format. RESULTS: A total of 90 studies were analyzed, there were 50 studies with 0–5 citation counts (55.56%), 18 studies with 5–10 citation counts (20%), 9 studies with 10–15 citation counts (10%), and 13 studies with more than 15 citation counts (14.44%). Eight (8.89%) studies were conducted by a supervision department, 38 (42.22%) by organizations with GCP qualification, and 44 (48.89%) by third parties. Additionally, there were some problems in the ethical review process of clinical trials, clinical trial registration process, clinical trial implementation process, and clinical trial reporting process. CONCLUSIONS: The current study shows that the quality problems of clinical trials in China still exist. The reported problems are related to the process of clinical trials, including ethical review, registration, implementation, reporting. Due to the limited quantity and quality of included studies, the conclusions of this study need to be verified by high-quality studies. REVIEW REGISTRATION: Not registerated in PROSPERO. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06281-1. |
format | Online Article Text |
id | pubmed-9034627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90346272022-04-24 Quality problems of clinical trials in China: evidence from quality related studies Fan, Jin Liu, Xiaobo Li, Yuxi Xia, Haisha Yang, Rong Li, Juan Zhang, Yonggang Trials Review BACKGROUND: Recently, the quality of clinical trials conducted in China has made considerable progress. However, clinical trials conducted in China still fall below the global average standard. The aim of this systematic review was to assess studies that investigated the quality of clinical trials conducted in China, summarize the issues, and provide suggestions for conducting high-quality clinical trials in China. METHODS: We comprehensively searched studies that investigated the quality of clinical trials conducted in China in the following databases from inception to December 1, 2021: National Knowledge Infrastructure, the Chinese Science and Technology Periodical Database, WanFang Data, China Biology Medicine, PubMed, and Embase. We then analyzed the issues in clinical trial registration, ethics review, implementation, and reporting. SPSS 25.0 software was used for data analysis. The data synthesis was conducted using summary statistics and a narrative format. RESULTS: A total of 90 studies were analyzed, there were 50 studies with 0–5 citation counts (55.56%), 18 studies with 5–10 citation counts (20%), 9 studies with 10–15 citation counts (10%), and 13 studies with more than 15 citation counts (14.44%). Eight (8.89%) studies were conducted by a supervision department, 38 (42.22%) by organizations with GCP qualification, and 44 (48.89%) by third parties. Additionally, there were some problems in the ethical review process of clinical trials, clinical trial registration process, clinical trial implementation process, and clinical trial reporting process. CONCLUSIONS: The current study shows that the quality problems of clinical trials in China still exist. The reported problems are related to the process of clinical trials, including ethical review, registration, implementation, reporting. Due to the limited quantity and quality of included studies, the conclusions of this study need to be verified by high-quality studies. REVIEW REGISTRATION: Not registerated in PROSPERO. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06281-1. BioMed Central 2022-04-23 /pmc/articles/PMC9034627/ /pubmed/35461304 http://dx.doi.org/10.1186/s13063-022-06281-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Fan, Jin Liu, Xiaobo Li, Yuxi Xia, Haisha Yang, Rong Li, Juan Zhang, Yonggang Quality problems of clinical trials in China: evidence from quality related studies |
title | Quality problems of clinical trials in China: evidence from quality related studies |
title_full | Quality problems of clinical trials in China: evidence from quality related studies |
title_fullStr | Quality problems of clinical trials in China: evidence from quality related studies |
title_full_unstemmed | Quality problems of clinical trials in China: evidence from quality related studies |
title_short | Quality problems of clinical trials in China: evidence from quality related studies |
title_sort | quality problems of clinical trials in china: evidence from quality related studies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034627/ https://www.ncbi.nlm.nih.gov/pubmed/35461304 http://dx.doi.org/10.1186/s13063-022-06281-1 |
work_keys_str_mv | AT fanjin qualityproblemsofclinicaltrialsinchinaevidencefromqualityrelatedstudies AT liuxiaobo qualityproblemsofclinicaltrialsinchinaevidencefromqualityrelatedstudies AT liyuxi qualityproblemsofclinicaltrialsinchinaevidencefromqualityrelatedstudies AT xiahaisha qualityproblemsofclinicaltrialsinchinaevidencefromqualityrelatedstudies AT yangrong qualityproblemsofclinicaltrialsinchinaevidencefromqualityrelatedstudies AT lijuan qualityproblemsofclinicaltrialsinchinaevidencefromqualityrelatedstudies AT zhangyonggang qualityproblemsofclinicaltrialsinchinaevidencefromqualityrelatedstudies |